Based on the Inari Medical Inc stock forecast from 11 analysts, the average analyst target price for Inari Medical Inc is USD 64.10 over the next 12 months. Inari Medical Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Inari Medical Inc is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Inari Medical Inc’s stock price was USD 79.40. Inari Medical Inc’s stock price has changed by +0.13% over the past week, +39.91% over the past month and +34.76% over the last year.
No recent analyst target price found for Inari Medical Inc
No recent average analyst rating found for Inari Medical Inc
Company Overview Inari Medical Inc
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. Read Less
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from ...Read More
Frequently Asked Questions About Inari Medical Inc (NARI) Stock
Based on ratings from 11 analysts Inari Medical Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 12 hold ratings.
Unfortunately we do not have enough data on NARI's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for NARI is USD 64.10 over the next 12 months. The maximum analyst target price is USD 80 while the minimum anlayst target price is USD 47.
Unfortunately we do not have enough data on NARI's stock to indicate if its overvalued.
The last closing price of NARI's stock was USD 79.40.
The most recent market capitalization for NARI is USD 4.64B.
Based on targets from 11 analysts, the average taret price for NARI is projected at USD 64.10 over the next 12 months.
This means that NARI's stock price may go down by -19.28% over the next 12 months.
We can't find any ETFs which contains Inari Medical Inc's stock.
As per our most recent records Inari Medical Inc has 1,300 Employees.
Inari Medical Inc's registered address is 6001 Oak Canyon, Irvine, CA, United States, 92618.
You can get more information about it from Inari Medical Inc's website at https://www.inarimedical.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Inari Medical Inc (NARI) Stock
Based on ratings from 11 analysts Inari Medical Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 9 buy, sell and 12 hold ratings.
Unfortunately we do not have enough data on NARI's stock to indicate if its a good dividend stock.
Based on targets from 11 analysts, the average taret price for NARI is USD 64.10 over the next 12 months. The maximum analyst target price is USD 80 while the minimum anlayst target price is USD 47.
Unfortunately we do not have enough data on NARI's stock to indicate if its overvalued.
The last closing price of NARI's stock was USD 79.40.
The most recent market capitalization for NARI is USD 4.64B.
Based on targets from 11 analysts, the average taret price for NARI is projected at USD 64.10 over the next 12 months.
This means that NARI's stock price may go down by -19.28% over the next 12 months.
We can't find any ETFs which contains Inari Medical Inc's stock.
As per our most recent records Inari Medical Inc has 1,300 Employees.
Inari Medical Inc's registered address is 6001 Oak Canyon, Irvine, CA, United States, 92618.
You can get more information about it from Inari Medical Inc's website at https://www.inarimedical.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NARI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
